CClinicalTrials.gg
CompletedNCT03219619Updated Oct 22, 2019

Effect of Cap-assisted Esophagogastroduodenoscopy on Observation of Major Duodenal Papilla

An interventional study of Cap-EGD and Duo in Observation of Major Duodenal Papilla (MDP), sponsored by Air Force Military Medical University, China. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Air Force Military Medical University, China · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Examination of major duodenal papilla (MDP) using a side-viewing duodenoscope is a golden standard. However, side-viewing duodenoscope is not available in some endoscopic centers. Cap-assisted esophagogastroduodenoscopy (Ca-EGD) using a transparent cap fitted to the tip of the scope has emerged as an alternative method for the observation of MDP. A recent study showed that complete examination of MDP could be achieved in 97% of patients. The investigators hypothesize that Ca-EGD is non-inferior to duodenoscope for the observation of MDP.

Read the detailed description

Interim analyses were planned to be performed by the data and safety monitoring board after data collection has been completed for 50% of the enrollment.

02

Conditions studied

  • Observation of Major Duodenal Papilla (MDP)
03

In context

Lead sponsor

Air Force Military Medical University, China is the lead sponsor of 172 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age > 18 years and \< 70 years
  • Patients with native MDP who underwent ERCP

Exclusion criteria

Exclusion Criteria:

  • Prior surgery in upper GI tract
  • Prior history of endoscopic sphincterotomy
  • Prior history of MDP treatment
  • Known or suspected obstruction of upper GI tract
  • Patients in poor condition who may not be suitable for Ca-EGD or duodenoscope
  • Pregnancy or lactic women
  • Inability to give informed consent
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Cap group: Cap-EGD

    Undergoing cap-assisted esophagogastroduodenoscopy

    Device: Cap-EGD

  • Active comparator
    Duo group: Duo

    Undergoing side-viewing duodenoscope

    Device: Duo

Interventions

  • DeviceCap-EGD

    Undergoing cap-assisted endoscopy

  • DeviceDuo

    Undergoing side-viewing duodenoscope

06

What researchers measure

Primary outcomes

  1. Rate of complete examination of MDP

    Complete examination is defined by visualization of both proximal and distal ends with orifice of papilla

    Time frame: 5 minutes after intubation of the esophagus

Secondary outcomes

  1. Endoscopic findings in descending duodenum

    All pathological findings which are seen in descending duodenum should be reported (e.g. ampullary adenoma, peripapillary diverticulum, ampullary carcinoma, inflammatory change of papilla, etc)

    Time frame: 5 minutes after intubation of the esophagus

  2. Overall endoscopic findings

    All pathological findings which are seen during the examination should be reported (e.g. reflux esophagitis, gastric cancer, gastric ulcer, duodenal ulcer, etc)

    Time frame: 5 minutes after intubation of the esophagus

  3. MDP examination time

    The times taken for the examination of the MDP (after passing the pylorus until examination of MDP)

    Time frame: 5 minutes after intubation of the esophagus

  4. MDP examination score

    Score 3 when proximal end, distal end and orifice were visualized; Score 2 when either proximal or distal end with orifice were visualized; Score 1 when either proximal or distal end without orifice was visualized; Score 0 when the MDP could not be localized

    Time frame: 5 minutes after intubation of the esophagus

07

Study locations

2 sites
  • Endoscopic center, Xijing Hospital of Digestive Diseases
    Xi'an, Shaanxi 710032, China
  • Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University
    Chongqing, 400010, China
08

References and documents

Publications

  • Shi X, Luo H, Ning B, Wang X, Tao Q, Liang S, Zhang R, Chen J, Luo B, Yao S, Pan Y, Guo X, Fan D. Effect of cap-assisted esophagogastroduodenoscopy on examination of the major duodenal papilla: a noninferior, randomized controlled trial. Endoscopy. 2019 May;51(5):427-435. doi: 10.1055/a-0767-6529. Epub 2019 Jan 8. PubMed 30620948 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03219619
Lead sponsor
Air Force Military Medical University, China
Responsible party
Yanglin Pan (Associate Professor, Air Force Military Medical University, China) — Principal investigator
First posted
Jul 17, 2017
Start date
Jul 20, 2018
Primary completion
Jul 20, 2018
Completion
Jul 20, 2018
Last update
Oct 22, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion